echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > FDA expands indications for Lynparza (olaparib)

    FDA expands indications for Lynparza (olaparib)

    • Last Update: 2022-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Breast cancer is cancer that develops from breast tissue


    breast cancer

    The FDA has expanded the approval of AstraZeneca and Merck & Co.


    FDA

    The approval was supported by results from the Phase III OlympiA trial, also published in NEJM


    Regarding the key secondary objective of overall survival (OS), the results showed that while Lynparza's 3-year estimated OS was higher than placebo, the difference was not significant at the interim analysis


    Regarding the key secondary objective of overall survival (OS), the results showed that while Lynparza's 3-year estimated OS was higher than placebo, the difference was not significant at the interim analysis


    Lynparza is already approved in the US, EU, Japan and several other countries for patients with gBRCAm, HER2-negative, metastatic breast cancer who have previously received chemotherapy


     

    Original source:

    Original source:

    https://firstwordpharma.


    https://firstwordpharma.
    com/story/5524473 https://firstwordpharma.
    com/story/5524473

    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.